FAQ  •  Register  •  Login

2024-Hardaker et al-Nat Commun

<<

mleipold

Guru

Posts: 7598

Joined: Fri Nov 01, 2013 5:30 pm

Location: Stanford HIMC, CA, USA

Post Mon Feb 26, 2024 6:54 pm

2024-Hardaker et al-Nat Commun

"The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment"
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa Carnevalli, Fernando J Calero-Nieto, Gemma N Jones, Andrew J Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J Carl Barrett, Arsene-Bienvenu Loembé, Serge Y Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A Nance, Carlos Alberto Gomez Roca, Elaine Cadogan, Susan E Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I Gabrilovich, Simon T Barry
Nat Commun. 2024, 15, 1700
https://doi.org/10.1038/s41467-024-45996-4

- no CyTOF dataset accession given
<<

mleipold

Guru

Posts: 7598

Joined: Fri Nov 01, 2013 5:30 pm

Location: Stanford HIMC, CA, USA

Post Thu Oct 09, 2025 7:39 pm

Re: 2024-Hardaker et al-Nat Commun

I think this has been released as FR-FCM-Z74F, based off of "Conclusion: The ATR inhibitor Ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumour microenvironment"

Return to Literature

Who is online

Users browsing this forum: No registered users and 11 guests